Brainsway Ltd (BWAY) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Brainsway Ltd stock (BWAY) is currently trading at $13.50. Brainsway Ltd PE ratio is 75.89. Brainsway Ltd PS ratio (Price-to-Sales) is 10.27. Analyst consensus price target for BWAY is $15.33. WallStSmart rates BWAY as Underperform.
- BWAY PE ratio analysis and historical PE chart
- BWAY PS ratio (Price-to-Sales) history and trend
- BWAY intrinsic value — DCF, Graham Number, EPV models
- BWAY stock price prediction 2025 2026 2027 2028 2029 2030
- BWAY fair value vs current price
- BWAY insider transactions and insider buying
- Is BWAY undervalued or overvalued?
- Brainsway Ltd financial analysis — revenue, earnings, cash flow
- BWAY Piotroski F-Score and Altman Z-Score
- BWAY analyst price target and Smart Rating
Brainsway
📊 No data available
Try selecting a different time range
BWAY Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Brainsway Ltd (BWAY)
BWAY trades 178% above its Graham fair value of $8.42, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Brainsway Ltd (BWAY) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth, eps growth. Concerns around price/sales and price/book. Mixed signals suggest waiting for clearer direction before acting.
Brainsway Ltd (BWAY) Key Strengths (2)
Earnings per share surging 390.80% year-over-year
Strong revenue growth at 27.40% annually
Supporting Valuation Data
Brainsway Ltd (BWAY) Areas to Watch (7)
Very expensive at 10.3x annual revenue
Very expensive at 7.3x book value
Thin operating margins with cost pressures present
Small-cap company with higher risk but more growth potential
Moderate profitability with room for improvement
Decent profitability, keeps $15 per $100 revenue
Moderate institutional interest at 35.11%
Supporting Valuation Data
Brainsway Ltd (BWAY) Detailed Analysis Report
Overall Assessment
This company scores 46/100 in our Smart Analysis, earning a D+ grade. Out of 9 metrics analyzed, 2 register as strengths (avg 9.0/10) while 7 fall into concern territory (avg 4.3/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on EPS Growth, Revenue Growth. Growth metrics are encouraging with Revenue Growth at 27.40%, EPS Growth at 390.80%.
The Bear Case
The primary concerns are Price/Sales, Price/Book, Operating Margin. Some valuation metrics including Price/Sales (10.27), Price/Book (7.33) suggest expensive pricing. Profitability pressure is visible in Return on Equity at 11.30%, Operating Margin at 13.20%, Profit Margin at 14.60%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Price/Sales improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 11.30% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 27.40% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Price/Sales and Price/Book are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
BWAY Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
BWAY's Price-to-Sales ratio of 10.27x sits near its historical average of 10x (57th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 0% below its historical high of 10.31x set in Mar 2026, and 9% above its historical low of 9.46x in Mar 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for Brainsway Ltd (BWAY) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
Brainsway Ltd is a strong growth company balancing expansion with improving profitability. Revenue reached 52M with 27% growth year-over-year. Profit margins of 14.6% are healthy, with room for further expansion as the business scales.
Key Findings
Revenue growing at 27% YoY, reaching 52M. This pace significantly outperforms most MEDICAL DEVICES peers.
ROE of 1130.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Free cash flow is -2M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Margin expansion: can Brainsway Ltd push profit margins above 15% as the business scales?
Growth sustainability: can Brainsway Ltd maintain 27%+ revenue growth, or will competition slow it down?
Valuation compression risk at a P/E of 75.9x. Any growth miss could trigger a sharp correction.
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact Brainsway Ltd.
Bottom Line
Brainsway Ltd offers an attractive blend of growth (27% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Brainsway Ltd(BWAY)
NASDAQ
HEALTHCARE
MEDICAL DEVICES
USA
Brainsway Ltd., a commercial-stage medical device company, focuses on the development and sale of non-invasive neuromodulation products in Israel and internationally. The company is headquartered in Jerusalem, Israel.